相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy
Matthew P. Goetz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.
Richard G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer
Matteo Lambertini et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients
Thomas Helland et al.
BREAST CANCER RESEARCH (2017)
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
Christian Jackisch et al.
BREAST CARE (2015)
Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective
Nynke G. L. Jager et al.
CLINICAL BREAST CANCER (2015)
Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer
P. Saladores et al.
PHARMACOGENOMICS JOURNAL (2015)
Adherence and discontinuation of oral hormonal therapy in patients with hormone receptor positive breast cancer
Lorena Rocha Ayres et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2014)
Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites
Nynke G. L. Jager et al.
BMC CANCER (2013)
A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians
Laetitia Huiart et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
Christina Davies et al.
LANCET (2013)
PharmGKB summary: tamoxifen pathway, pharmacokinetics
Daniel J. Klein et al.
PHARMACOGENETICS AND GENOMICS (2013)
Clinical and biomarker predictors of side effects from tamoxifen
Wendy Lorizio et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Patient-Reported Discontinuation of Endocrine Therapy and Related Adverse Effects Among Women With Early-Stage Breast Cancer
Erin J. Aiello Bowles et al.
JOURNAL OF ONCOLOGY PRACTICE (2012)
Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer
L. Huiart et al.
BRITISH JOURNAL OF CANCER (2011)
Increasing Tamoxifen Dose in Breast Cancer Patients Based on CYP2D6 Genotypes and Endoxifen Levels: Effect on Active Metabolite Isomers and the Antiestrogenic Activity Score
M. F. Barginear et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
L. Madlensky et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study
William J. Irvin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients
Dawn L. Hershman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer
Cynthia Owusu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The effect of tamoxifen on the genital tract
Sandra A. Polin et al.
CANCER IMAGING (2008)
Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism
J. Gjerde et al.
ANNALS OF ONCOLOGY (2008)
Side effects of aromatase inhibitors versus tamoxifen: the patients' perspective
Jennifer R. Garreau et al.
AMERICAN JOURNAL OF SURGERY (2006)
Adherence to tamoxifen over the five-year course
Timothy L. Lash et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Validity of a prescription claims database to estimate medication adherence in older persons
R Grymonpre et al.
MEDICAL CARE (2006)
Hot flushes in breast cancer patients
CH Mom et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
B Fisher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
A selective estrogen receptor modulator, tamoxifen, and membrane fluidity of erythrocytes in normotensive and hypertensive postmenopausal women: An electron paramagnetic resonance investigation
K Tsuda et al.
AMERICAN JOURNAL OF HYPERTENSION (2005)
Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer
L Gallicchio et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
AH Partridge et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver
JK Coller et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women
S Demissie et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
分享论文
